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Edited by Beat ImhofAbstract The GTPase RhoA is essential for the development of
pre-T cells in the thymus. To investigate the mechanisms used by
RhoA to control thymocyte development we have used Aﬀyme-
trix gene proﬁling to identify RhoA regulated genes in T cell pro-
genitors. The data show that RhoA plays a speciﬁc and essential
role in pre-T cells because it is required for the expression of
transcription factors of the Egr-1 and AP-1 families that have
critical functions in thymocyte development. Loss of RhoA func-
tion in T cell progenitors causes a developmental block that
pheno-copies the consequence of losing pre-TCR expression in
Recombinase gene 2 (Rag2) null mice. Transcriptional proﬁling
reveals both common and unique gene targets for RhoA and
the pre-TCR indicating that RhoA participates in the pre-TCR
induced transcriptional program but also mediates pre-TCR
independent gene transcription.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V.
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The T cell antigen receptor (TCR) complex comprises vari-
able a/b subunits that recognise peptide/major histocompati-
bility (MHC) complexes and invariant signal transduction
subunits of the CD3 antigen. A key stage in T cell development
in the thymus is the selection of cells that have successfully
rearranged their TCR-b locus. This occurs in T cell precursors,
which do not express of the MHC receptors, CD4 and CD8
(double negative (DN) thymocytes) [1]. The DN stages of
intrathymic diﬀerentiation can be followed by the sequential
pattern of expression of CD44 and CD25. T cell progenitors
enter the thymus as CD44+CD25 cells (termed DN1); these
then express CD25 (DN2) and begin to rearrange T-cell recep-
tor b loci. Cells then lose CD44 expression and continue b
chain rearrangements to completion (DN3). Cells that success-
fully rearrange their TCR-b locus will express a functional
receptor complex known as the pre-TCR comprising a TCR-
b chain, the p-Ta subunit and the signalling subunits of the
CD3 antigen [2–4]. When the pre-TCR is expressed at the cell
membrane it promotes cell survival and entry into the cell cycle
[5]; cells downregulate CD25 and transit to the DN4 pre-T cell*Corresponding author. Fax: +44 1382 345783.
E-mail address: d.a.cantrell@dundee.ac.uk (D. Cantrell).
0014-5793 2007 Federation of European Biochemical Societies. Published
doi:10.1016/j.febslet.2007.07.077subset. DN4 T cells undergo proliferative expansion and diﬀer-
entiate to CD4+CD8+ double positive (DP) cells. These cells
then undergo TCR a-chain gene rearrangements and upon
expression of a functional a/b TCR complex are subjected to
positive and negative selection to generate CD4+ or CD8+ sin-
gle positive (SP) thymocytes [6–8].
Normal pre-T cell development requires the coordination of
a complex program of gene transcription by signal transduc-
tion networks mediated by the pre-TCR complex and cytokine
and stromal signals [9,5]. Mice deﬁcient for the recombinase
activating (RAG) genes which are unable to rearrange TCR-
b subunits and express a pre-TCR are unable to progress
beyond the DN3 stage of thymocyte development [10]. Simi-
larly, the absence of pre-Ta or CD3 subunits blocks thymocyte
development at the DN3 stage [11,3]. The transition of thymo-
cytes beyond the pre-T cell stage of thymocyte diﬀerentiation is
also dependent on signal transduction networks mediated by
tyrosine and serine kinases [3,12,13]. In this context, crucial
responses are mediated by Rho family guanine nucleotide
binding proteins such as RhoA, Rac-1 and CDC42 [14–17].
The importance of RhoA for thymocyte development has
been demonstrated by studies of transgenic mice that express
Clostridium botulinum C3-transferase under the control of T
cell speciﬁc promoters such as the p56lck and CD2 promoters
[17,15,18]. This toxin selectively ADP-ribosylates RhoA within
its eﬀector-binding domain and abolishes its biological func-
tion. Transgenic mice that express C3-transferase under the
control of the p56Lck promoter have a small thymus and
severely reduced numbers of peripheral T cells [15,17]. This
phenotype is caused by survival defects in DN2 and DN3 thy-
mocytes that lack Rho function [15]. During embryogenesis no
cells progress beyond the DN1 stage but in adult mice a few T
cell progenitors survive and develop to DN4s and beyond [15].
This ‘leakiness’ either reﬂects selection of cells that compensate
for loss of Rho function in DN2/3 thymocytes or reﬂects het-
erogeneous and asynchronous expression of the lck promoter
in adult DN thymocytes. The few DP thymocytes and mature
T cells found in adult Lck-C3 transgenic mice have numerous
defects including reduced survival, proliferation, integrin med-
iated cell adhesion and defective cell motility [15,19]. A com-
plementary strategy to probe Rho function in the thymus
used the CD2 locus control region (LCR) to target C3 transfer-
ase to T cell progenitors (CD2–C3 mice) [18]. The inhibition of
Rho function at the DN2/3 stage in CD2–C3 mice is not leaky
and causes T cells to become blocked in diﬀerentiation at the
DN3 stage of thymus development. CD2–C3 mice thus have
a thymic phenotype indistinguishable from the phenotype of
Recombinase gene null mice or mice lacking key structuralby Elsevier B.V. Open access under CC BY-NC-ND license.
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thymocyte development is blocked at the pre-T cell/DN3 stage
[18].
The basis for the failure of pre-T cell diﬀerentiation in CD2–
C3 transferase mice is not known. One way to address this
issue is to use microarray gene expression proﬁling to deter-
mine the impact of losing Rho function on transcriptional
responses in pre-T cells. Previous studies in transformed cell
lines have identiﬁed a role for RhoA in regulating activating
protein-1 (AP1) family of transcription factors [22–24] but
transcriptional targets for RhoA signal transduction in pri-
mary non-transformed cells have not been explored. The pres-
ent data show that RhoA regulates expression of genes
encoding members of the Fos/Jun and early growth response
(Egr) family of transcription factors but also has an impact
on expression of genes regulating diverse biological functions
including serine/threonine kinases, protein phosphatases,
enzymes that regulate protein biosynthesis and proteins that
regulate nuclear structure and function.2. Materials and methods
2.1. Mice
Mice were bred and maintained under speciﬁc pathogen-free condi-
tions in the transgenic animal unit. RAG2/ and C3 transgenic mice,
which selectively express the bacterial toxin C3-transferase under the
control of CD2 promoter and locus control region in the thymus, have
been described in detail elsewhere [10,18].2.2. Flow cytometric analysis
Fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophyco-
cyanin (APC), and biotin-conjugated antibodies were obtained from
Pharmingen (San Diego, CA). Tricolour (PE/Cy5 and APC/Alexa750)
conjugated antibodies and ﬂuorophore-streptavidin conjugates were
from Caltag (Burlingame, CA). Thymocytes were stained for cell sur-
face markers and analysed on a FACS Calibur (Becton Dickinson
Immunocytometry Systems Franklin Lakes CA). Data were analysed
using CellQuest BDIS or FlowJo (Treestar Inc, Ashland OR) software.
CD4CD8 double negative thymocyte subsets were analysed for
CD44 and CD25 expression following lineage exclusion of mature
DP and SP cells as well as non-T cell lineage cells using a cocktail of
biotinylated antibodies (CD4, CD8, CD3 B220, Mac-1, NK, Gr-1,
and cd) revealed with streptavidin-tricolour and costained with
CD25-FITC, CD44-PE and Thy1.2-APC. Intracellular phospho-S6
and TCR-b intracellular staining was carried out on thymocytes pre
stained to identify DN3 and DN4 subpopulations. Cells were subse-
quently ﬁxed in 1% paraformaldehyde for 10 min at room temperature,
washed in PBS and permeabilized with saponin buﬀer (0.5% saponin,
5% FBS, 10 mM HEPES [pH 7.4] in PBS) for 10 min at room temper-
ature. Permeabilized cells were incubated with PE-conjugated TCRb
antibody and phospho S6 antibody for 45 min at room temperature,
washed in saponin buﬀer and subsequently stained with FITC conju-
gated donkey anti rabbit IgG (Jackson Immunoresearch, West Grove
PA). Cells were analysed on an LSR Flow Cytometer (BDIS).2.3. RNA extraction
Thymocytes were isolated from 4- to 6-week-old RAG2/, CD2–C3
and C57BL/6 control mice. DN3 pre-T cells were puriﬁed ﬁrstly by
removing CD4, CD8 DP cells using MACS CD4+ and -MACS
CD8+ T cell isolation kits (Miltenyi Biotec, Ltd.) followed by magnetic
autoMACS separation. CD4/CD8 depleted thymocytes were then
labelled with Thy1.2-APC, PE conjugated CD4, CD8, CD44 and
TCRcd antibodies, FITC conjugated CD25 antibodies and the DN3
subpopulation (Thy1+CD4/CD8/CD44/CD25+) was puriﬁed by
cell sorting on a FACS Vantage (BDIS) using Cell Quest software
(BDIS). All sorted cells were analysed by ﬂow cytometry and only used
for experiments if the purity was 95–98%. Total RNA was extracted
from sorted cells using the Qiagen RNeasy kit according to manufac-turers instructions. Total RNA was quantiﬁed using the RNA 6000
Nano LabChip kit and analyzed on an Agilent 2100 Bioanalyzer
(Agilent Technologies). Total RNA from up to 10 thymi were pooled
for microarray analysis and quantitative PCR.
2.4. Microarray
Microarray analysis was carried out by the Finnish DNA Micro-
array Centre at the Centre for Biotechnology, Turku, Finland. For
Aﬀymetrix sample preparation, 100–1000 ng of total RNA was used
as the starting material to synthesise target cRNA using the Gene-
Chip Eukaryotic Small Sample Target Labeling Assay Version II
according to manufacturers’ instructions (Aﬀymetrix, Santa Clara,
CA). The cRNA target sample was hybridised to the Aﬀymetrix
Mouse Genome 430 2.0 Array (45,101 probes sets and expressed
sequence tag (EST) clusters). Data was analysed with Aﬀymetrix Gene
Chip Operating Software (GCOS) version 1.1 and ﬁltered according to
recommendations of the manufacturer. Comparison analysis was used
to compare the expression proﬁles from two arrays – results were ob-
tained by analyzing the experimental array in comparison to the base-
line array. The global method of scaling was used for normalizing
hybridization intensity between arrays. The statistical algorithm used
by GCOS deﬁned the expression status of each gene-speciﬁc probe
set as not changed, increased, marginally increased, decreased or mar-
ginally decreased. Genes that were absent or unchanged between com-
parisons were excluded from the results. Comparison analysis deﬁnes a
gene as up-regulated if the signal log ratio between the baseline sample
and the experimental sample is larger than 1 (2-fold) and the experi-
mental sample is present. Similarly changed genes were further ana-
lyzed/classiﬁed using the gene ontology tool (www.Aﬀymetrix.com)
and represented by biological function. Gene lists were complied and
sorted by genes that were either commonly or uniquely regulated in
CD2-C3 and RAG2/ thymocytes.
2.5. Real-time RT-PCR analysis
Puriﬁed total RNA (200 ng) was reverse transcribed using the
iScript cDNA synthesis kit (BioRad). Real time RT-PCR was
performed in a 96-well plate using iQ SYBR Green based detection
(BioRad) on a BioRad iCycler in 20 ll reaction volume containing
1 ll cDNA (20 ng), 0.8 ll 10lM sense and antisense primers, 10 ll
iQ SYBR Green supermix, and 4 ll nuclease free water. Each reac-
tion was performed in duplicate and each experiment repeated in trip-
licate. 18S rRNA levels were used to normalise RNA concentrations
between samples and the relative mRNA levels were calculated using
the equation:
EðctucctusÞu
EðctrcctrsÞr
where E is the eﬃciency of PCR, ct is the threshold cycle, u is the
mRNA of interest, r is the reference gene (18S rRNA), s is the sample
and c is the control sample. Primers used for RT-PCR were designed
using Beacon Designer 2 software. Primer sequences are: Egr1 forward
5 0-ACAGAAGGACAAGAAAGCAGAC-3, reverse 5-CCAGGA-
GAGGAGTAGGAAGTG-3 0, Fos forward 5 0-CTACTGTGTTCCT-
GGCAATAGC-3 0, reverse 5 0-AACATTGACGCTGAAGGACTAC-
3 0, Egr3 forward 5 0-TGACCAACGAGAAGCCCAATC-3 0, reverse
5 0-GCTAATGATGTTGTCCTGGCAC-3 0, Jun forward 5 0-CGCCT-
CGTTCCTCCAGTC-3 0 reverse 5 0-ACGTGAGAAGGTCCGAG-
TTC-3 0, JunB forward 5 0-CTTCTACGACGATGCCCTCAAC-30,
reverse 5 0-GTTCAAGGTCATGCTCTGTTTTAGG-3 0, Nur77
forward 5 0-CCTGTTGCTAGAGTCTGCCTTC-3 0, reverse 5 0-
CAATCCAACACCAAAGCCACG-30, 18S RNA forward 5 0-
GTAACCCGTTGAACCCCATT-3 0, reverse 5 0-CCATCCAATCG-
TAGTA-3 0.3. Results and discussion
Mice expressing the RhoA inhibitor Clostridium Botulinum
C3 transferase under the control of the CD2 locus control re-
gion (LCR) have been described previously [18]. Loss of RhoA
function in CD2-C3 mice results in loss of CD4/CD8 double
positive thymocytes (Fig. 1A) with a block in thymocyte
Fig. 1. Expression of C3 transferase in the thymus of adult mice prevents up regulation of thymocyte developmental markers. (A) Data show ﬂow
cytometry analysis of CD4 and CD8 expression on Thy1+ thymocytes from CD2–C3, RAG2/ and C57BL/6 control mice. (B) Data show ﬂow
cytometry analysis of CD25 and CD44 expression on Thy1+ CD4CD8 thymocytes from CD2-C3, RAG2/ and C57BL/6 control mice. (C)
Histograms show intracellular TCR-b staining in DN3 cells (CD44CD25+ Thy1+ CD4CD8) from wild type or CD2–C3 transferase mice.
Isotype-matched control antibody shows negative staining (dotted line). In 5 experiments, TCR-b positive cells in wild type DN3s averaged 24%
(range 20–25%) whereas in CD2–C3 DN3s averaged 10% (range 7.35–11.47%).
M. Mullin et al. / FEBS Letters 581 (2007) 4309–4317 4311development at the DN3 stage (Fig. 1B). Rag2/ mice also
block thymus development at the DN3 stage (Figs. 1A and
B) due to failed expression of the pre-TCR complex. Despite
this superﬁcial similarity, loss of Rho function does not
prevent TCR beta locus rearrangements although there is a
reduced frequency of DN3 cells expressing intracellular
TCR-b subunits (Fig. 1C). Ectopic expression of transgenic
TCR complexes cannot reverse the developmental block in
CD2–C3 thymocytes demonstrating that failed expression of
TCR complexes does not explain the developmental defects
caused by loss of Rho function [18]. Rho thus appears neces-sary for pre-TCR function although these results do not dis-
criminate between a direct role for RhoA in pre-TCR
signalling or a role for this GTPase in the cytokine/stromal sig-
nalling pathways that synergise with pre-TCR signals to con-
trol pre-T cell diﬀerentiation [25–27].
CD2–C3 transferase mice provide a good model system to
probe the immediate transcriptional consequences of losing
RhoA function in pre-T cells since the CD2-LCR initiates
expression of transgenes in T cell progenitors as they transit
from the DN2 to DN3 stage of thymocyte development [18].
Accordingly, it is possible to isolate DN3 thymocytes ex vivo
4312 M. Mullin et al. / FEBS Letters 581 (2007) 4309–4317that have only just switched on expression of C3 transferase
and prepare RNA for DNA microarray analysis. The Aﬀyme-
trix Mouse Genome 430 2.0 array, representing 39000 murine
gene transcripts, was used to transcriptionally proﬁle DN3 pre-
T cells puriﬁed from the thymi of CD3–C3 transgenic mice. In
these experiments DN3 thymocytes from wild type control
mice were transcriptionally proﬁled and used for comparisons.
The microarray data were analyzed with the Aﬀymetrix
Gene Chip Operating Software (GCOS, version 1.1) by com-
paring the gene expression proﬁles of CD2–C3 pre-T cells to
the proﬁle of normal cells to reveal changes above or belowFig. 2. Transcriptional changes caused by loss of endogenous RhoA function
display a 10-fold or greater reduction in expression in CD2–C3 DN3 cells com
value indicates a fold decrease. (B) The table displays total number of transcr
CD2–C3 DN3 thymocytes compared to wild type DN3 cells. (C) Real time
CD2–C3 DN3 cells compared to wild type DN3 cells. Error bars indicate the
Table showing comparison of transcription factors downregulated in RAG2wild type levels. DN3 pre-T cells expressed approximately
18000 genes and there were only small changes in the tran-
scriptional proﬁle of CD2–C3 DN3 thymocytes compared to
control wild type DN3s. We focused our analysis on P 2-fold
changes, which were further analyzed using the Aﬀymetrix
gene ontology tool. A full list of the genes regulated 2-fold
or greater by loss of RhoA function in DN3 thymocytes is
shown in Supplementary Fig. 1. There were approximately
18000 genes expressed in wild type DN3 thymocytes: loss of
RhoA function caused a P 2-fold decrease in expression of
383 genes and a P 2-fold increase in expression of 190 genes.in DN3 pre-T cells. (A) Table showing the diverse number of genes that
pared to wild type DN3 cells. The symbol (–) preceding the numerical
iption factors that display a 2-fold or greater reduction in expression in
PCR analysis of several transcription factor genes downregulated in
standard deviation obtained from three independent experiments. (D)
/ DN3 cells with CD2–C3 DN3 cells.
Fig. 2 (continued)
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with diverse biological functions including serine/threoninekinases, protein phosphatases, enzymes that regulate protein
biosynthesis.
Fig. 3. Diﬀerential gene comparison in DN3 pre-T cells lack either
endogenous RhoA function or TCR-b signalling. Venn diagrams
showing the number of genes that are uniquely and commonly
regulated in CD2–C3 DN3s (lacking RhoA function) versus RAG2/
DN3s (lacking TCR-b signalling). The region of overlap regulates
genes that are commonly regulated. Gene changes 2-fold and above are
shown.
4314 M. Mullin et al. / FEBS Letters 581 (2007) 4309–4317This point is illustrated in Fig. 2A, which shows the genes
whose expression is regulated more than 10-fold. The largest
decrease was in expression of the gene encoding FosL2, a
Fos family transcription factor (630-fold decrease) but other
large changes included a subunit of eukaryotic translation ini-
tiation factor 2, Protein Kinase C beta and the membrane
receptor CD69. There was also a loss of expression of genes
encoding proteins that regulate nuclear structure and function
such as genes encoding histones that are involved in nucleo-
some assembly. In a similar category there was reduced expres-
sion of mRNA encoding special AT-rich sequence binding
protein 1 (SATB1) in CD2-C3 DN3s (Supplementary Fig. 1).
SATB1 acts as a scaﬀold for chromatin modiﬁers and is known
to regulate higher order chromatin structure and to regulate
gene expression by acting as a ‘‘docking site’’ for several chro-
matin remodeling enzymes [28–30].
Of 55 genes whose expression was decreased P 5-fold, 23
encoded transcription factors; of 384 genes decreased P 2-
fold, 63 were transcription factors (Fig. 2B). Transcription fac-
tors downregulated in CD2-C3 DN3 thymocytes included
Kruppel family transcription factors KLF4, KLF6 and
KLF9. There was also loss of expression of members of the
immediate early gene family Egr1 and Egr3, AP-1 family mem-
bers Fos, FosL2, FosB, Jun, JunB and downregulated expres-
sion of genes encoding Ets1 and Nurr77. To validate the
microarray analysis, quantitative real-time PCR was used to
compare expression of a selection of these diﬀerent transcrip-
tion factors in wild type versus CD2-C3 thymocytes
(Fig. 2C). The experiments conﬁrmed the reduction in Fos,
Jun, JunB, Egr1 and Egr3 and NURR77 in CD2–C3 DN3s
compared to wild type controls.
A number of gene targets for Egr transcription factors have
been described [31] and in this context, RhoA inactivation
caused loss of expression of multiple members of the MAP
kinase phosphatase family DUSP 1, 2, 4, 6, 16. The latter
are induced in negative feedback mechanisms that modulate
MAP kinase activity and have been described as targets for
Egr family transcription factors [31–33]. The loss of DUSP
expression is thus almost certainly a secondary consequence
of failed expression of Egr molecules. Egr1 and Egr3 are well
characterised pre-TCR induced genes [34–38]. To verify this
we compared the transcriptional proﬁle of CD2-C3 DN3s with
Recombinase gene 2/ (RAG2/) DN3s which lack expres-
sion of the pre-TCR complex because they fail to rearrange
their TCR beta locus. Of the 23 transcription factors downreg-
ulated P 5-fold in CD2–C3 thymocytes 18 were also downreg-
ulated in Rag2/ DN3s (Fig. 2D) and these included Egr1,
Egr3, Fos, Fosl2, FosB, Ets1, Nurr77. These microarray anal-
yses were conﬁrmed by quantitative real-time PCR analysis of
wild type versus Rag2/ thymocytes (data not shown). The
common loss of expression of members of the Egr family in
CD2–C3 and Rag2/ pre-T cells is thus consistent with a
RhoA requirement for the pre-TCR induced gene transcrip-
tion. However, comparisons of the total number of genes
regulated uniquely in CD2–C3 and Rag2/ DN3s (Fig. 3)
(VENN diagrams) indicate that there are a number of gene
changes in CD2–C3 cells that are not seen in Rag2/ DN3s.
The full list of genes that were commonly and uniquely regu-
lated 2-fold and greater in CD2 C3 versus Rag2/ pre-T cells
is shown in Supplementary Fig. 2. In terms of P 2-fold, gene
repression, CD2-C3 and Rag2/ DN3s had 180 gene targetsin common with 202 genes being downregulated uniquely in
CD2–C3 pre-T cells and 120 genes downregulated uniquely
in Rag2/ cells. In terms of P 2-fold gene increases, CD2–
C3 and Rag2/ DN3s had 65 gene targets in common, 129
genes that were increased uniquely in CD2-C3 DN3s and
182 increased uniquely in Rag2/ cells (Fig. 3).
The common transcriptional changes caused by loss of the
pre-TCR in Rag2/ DN3s or loss of Rho function in CD2–
C3 mice indicates that Rho function is necessary for some
pre-TCR induced transcriptional responses. However, there
are genes downregulated in DN3s lacking RhoA function that
are unchanged in Rag2/ DN3s (Supplementary Fig. 3) indi-
cating that RhoA is not just required to mediate the preTCR
induced gene program but may also participate in cytokine/
stromal cell-initiated signalling pathways that control pre-T
cell diﬀerentiation. The genes uniquely lost in CD3–C3 DN3
thymocytes include serine kinases (Protein Kinase C beta
and Map3k14); transcription factors (SpiB and Dlx1) and
regulators of protein biosynthesis (Eif2s3y) (Supplementary
Fig. 3). One gene of interest lost in CD2–C3 DN3s but not
Rag2 null DN3s was Hes-1 which is induced by Notch recep-
tor-ligand interactions. Notch signalling is required through-
out DN to DP stage of thymocyte development to support T
cell metabolism and survival [39–42]. A RhoA requirement
for Notch signalling has not been described but it is known
that RhoA is necessary for integrin mediated cell adhesion
and thymocyte cell migration [19]. Accordingly, decreased
Hes-1 expression could reﬂect that pre-T cells lacking Rho
function cannot make normal contacts with stromal cells that
express the Notch ligands [43,42,44,45].
There were also unique transcriptional changes seen in
Rag2/ cells that were not found in the CD2–C3 DN3s (Sup-
plementary Fig. 4) which indicates that the pre-TCR can
regulate a program of gene transcription via RhoA indepen-
dent pathways The unique changes in Rag2/ cells not sur-
prisingly included loss of expression of rearranged TCR-b
subunits. One other gene downregulated in Rag2/ DN3s
but not CD2–C3 DN3s was RPS6, which encodes the ribo-
somal S6 subunit. In this respect, we recently described high
basal levels of S6 phosphorylation in ex vivo b selected
DN3s and no detectable S6 phosphorylation in ex vivo
Rag2/ DN3s [13]. The data in Fig. 4 quantify S6 phosphor-
ylation in CD2–C3 DN3s compared to wild type cells. Normal
DN3s are heterogeneous for phosphoS6 with the majority of
Fig. 4. Endogenous RhoA function is not required for pre-TCR induced phosphorylation of S6. FACS histograms shows intracellular TCR-b
staining proﬁles (left panel) for wild type and CD2–C3 DN3 cells and subsequent levels of phospho-S6 (right panel) in TCR-b low or high DN3 cells.
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are phosphoS6high. The DN3 thymocyte subpopulation can
be subdivided into cells that have not yet completed TCR-b
locus rearrangements and those that express a functional
TCR-b subunit that allows surface expression and signalling
of the pre-TCR complex. Analysis of TCRb expression by
intracellular staining revealed that DN3s that express icTCR-
b chains are generally phosphoS6high whereas DN3s that are
icTCR-b null are uniformly phosphoS6low. In CD2–C3
DN3s there were also high levels of phosphoS6 in TCR-b high
cells. The presence of normal S6 phosphorylation in b selected
DN3s lacking Rho function is a further indication that Rho is
necessary for a subset of responses in DN3 thymocytes but
does not globally block signalling.
One important question is whether the transcriptional
changes in CD2–C3 DN3s explain why loss of RhoA function
results in failed thymocyte diﬀerentiation? In this respect,
microarray analysis of Rag2/ pre-T cells revealed decreased
expression of TCR-b subunits as a major defect (Supplemen-
tary Fig. 4) and failed expression of the TCR-b subunit is
indeed responsible for the DN3 developmental block in
Rag2/ mice. In CD2–C3 DN3s there were several gene de-
fects that would explain why RhoA function is essential for
pre-T cell development. For example, RhoA is required for
expression of Egr3 and Ets1 and loss of either of these tran-
scription factors inhibits pre-T cell proliferation and is subop-
timal for transition through early pre-TCR-dependent stages
of thymocyte development [46,36]. Loss of individual Egr fam-
ily or AP-1 transcription factors does not completely abrogate
thymocyte diﬀerentiation but this reﬂects that there is consid-
erable redundancy in AP-1 complexes due to the ability of
diﬀerent family members to pair as dimers [47–49]. The simul-
taneous elimination of Egr1, Egr3, Ets1 and multiple Fos/Jun
family members in CD2–C3 DN3s would circumvent the pos-
sibility of redundancy [50,51]. This comprehensive loss of AP-1
activity in pre-T cell lacking RhoA function plus the decreased
expression of other transcription factors would rapidly causeglobal changes in the transcriptional program of a cell. More-
over, the transcription factor defects would be exacerbated by
the decreased expression of chromatin modifying enzymes
such as SATB1.
In summary, loss of Rho function or failed expression of the
pre-TCR complex in Rag2/ null mice block T cell develop-
ment at a common stage. The present data show that the
genetic consequences of loss of Rho function versus loss of
pre-TCR expression for T cell progenitors are not identical.
The present results also show that loss of Rho function in pre-
T cells results in downregulation of genes encoding members
of the Fos/Jun and Early growth response (Egr) family of tran-
scription factors. The collective loss of these transcription fac-
tors and the resultant secondary genetic changes explains why
loss of RhoA function prevents pre-T cell development.
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